Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554103 | 0.83 | BCL2L1 (0.67) | BCL2L1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL5559016 | 0.82 | BCL2L1 (0.53) | BCL2L1CETPSMPD1ALDH1A1LMNA | |
| SCHEMBL5560532 | 0.79 | CETP (0.43) | BCL2L1CETPSMPD1ALDH1A1LMNA | |
| SCHEMBL5554648 | 0.78 | CYP2C9 (0.46) | BCL2L1CETPALDH1A1LMNAKDM4E | |
| SCHEMBL4652440 | 0.78 | BCL2L1 (0.58) | BCL2L1CETPSMPD1ALDH1A1LMNA | |
| SCHEMBL4651677 | 0.78 | BCL2L1 (0.58) | BCL2L1CETPSMPD1ALDH1A1LMNA | |
| SCHEMBL25798826 | 0.75 | CETP (0.59) | CETPALDH1A1LMNAMAPK1KDM4E | |
| SCHEMBL4652272 | 0.75 | BCL2L1 (0.62) | BCL2L1CETPSMPD1ALDH1A1LMNA | |
| SCHEMBL4652385 | 0.75 | CETP (0.53) | CETPSMPD1ALDH1A1LMNAMAPK1 | |
| SCHEMBL17805815 | 0.74 | BCL2L1 (0.84) | BCL2L1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594512-A4 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION | KEMIA INC (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1594512-A2 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION | Kemia, INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040248850-A1 | Compounds for the treatment of HIV infection | KEMIA, INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004071426-A2 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION | KEMIA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248850-A1 | Compounds for the treatment of HIV infection | CCR5, CD4, HAVCR2 | BCL2L1 2807/4885CETP 322/4885SMPD1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.